SIGNIFICANTLY MORE PATIENTS WERE URTICARIA-FREE AT
WEEK 24

CUPID-A

Proportion of patients at Week 24

urticaria-free (UAS7=0; Week 24, secondary endpoint)^1,2

well-controlled symptoms (UAS7≤6; Week 24, secondary endpoint)^1,2

≈2.5x AS MANY PATIENTS^a

32%

13%

≈2x AS MANY PATIENTS^b

47%

24%

DUPIXENT (n=68) Placebo (n=68)

^a P=0.0133; OR (95% CI): 3.09 (1.24, 7.69).

^b P=0.0034; OR (95% CI): 3.23 (1.43, 7.27).

CUPID-C

≈1.8x

as many patients were urticaria-free
(UAS7=0) at Week 24;

30% on DUPIXENT (n=73) vs 17% on placebo
(n=75; P=0.0165; secondary endpoint)^1,2,c

≈1.7x

as many patients had well-controlled
symptoms (UAS7≤6) at Week 24;

40% on DUPIXENT (n=73) vs 23% on placebo
(n=75; P=0.0062; secondary endpoint)^1,2,d

^cOR (95% CI): 2.73 (1.15, 6.50).

^dOR (95% CI): 3.05 (1.32, 7.02).

CI, confidence interval; OR, odds ratio; UAS7, urticaria activity score over 7 days.

Dosage and
administration

Thinking about prescribing DUPIXENT?
Find the information you need to get started.

SIGNIFICANTLY MORE PATIENTS WERE URTICARIA-FREE AT WEEK 24